Device Next Generation Sequencing Based Tumor Profiling Test

Pgdx Elio Tissue Complete

Payments companies reported to CMS as associated with Pgdx Elio Tissue Complete. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.

$3,839associated payments (2023-2025)
23clinicians with associated payments
3companies reporting

By year

2023 $1,417
2024 $1,156
2025 $1,266

Payments reported as associated with Pgdx Elio Tissue Complete, per program year, as reported to CMS.

Who makes it

Specialties most often involved

Anatomic Pathology & Clinical Pathology $1,599
Anatomic Pathology $607
Clinical Pathology $367
Clinical Pathology/Laboratory Medicine $294
Clinical Molecular Genetics $215
Clinical Cytogenetics $215

Where the associated payments went, by the receiving clinician's specialty.

Clinicians most associated with Pgdx Elio Tissue Complete

These are the largest totals companies reported as associated with Pgdx Elio Tissue Complete. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.

ClinicianLocationSpecialtyAssociated payments (2023-2025)
Shuko Harada Birmingham, AL Anatomic Pathology & Clinical Pathology $395.73
Alexander Mackinnon Birmingham, AL Anatomic Pathology $395.73
Rachel Starks Sioux Falls, SD Anatomic Pathology & Clinical Pathology $327.88
Yaolin Zhou Greenville, NC Anatomic Pathology & Clinical Pathology $293.85
Ying Zhang Orange, CA Clinical Molecular Genetics $214.88
Catherine Stefaniuk Cincinnati, OH Anatomic Pathology & Clinical Pathology $214.88
Guang Liu Chandler, AZ Clinical Cytogenetics $214.88
Nefize Kip Nashville, TN Anatomic Pathology & Clinical Pathology $180.85
Annette Kim Ann Arbor, MI Clinical Pathology $180.85
Hiroko Shike Hershey, PA Clinical Pathology/Laboratory Medicine $180.85

Prescribed Pgdx Elio Tissue Complete?

See what its makers reported for your doctor. Two steps, private, no account.

Check my doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.